PKO Investment Management Joint-Stock’s Intellia Therapeutics NTLA Stock Holding History

PKO Investment Management Joint-Stock’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-91,939	Closed	-$2.52M	–	96
2018 Q2	$2.52M	Sell	91,939 -56,763	-38%	-$1.38M	0.53%	37
2018 Q1	$3.14M	Buy	148,702 +59,700	+67%	+$1.47M	0.7%	26
2017 Q4	$1.71M	Buy	89,002 +76,186	+594%	+$1.76M	0.43%	50
2017 Q3	$318K	Buy	12,816 +6,000	+88%	+$113K	0.09%	75
2017 Q2	$109K	Buy	+6,816	New	+$95.2K	0.04%	73

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

PKO Investment Management Joint-Stock's NTLA Position: Q3 2018 in Review

PKO Investment Management Joint-Stock sold out of Intellia Therapeutics (NTLA) in Q3 2018, closing a stake of 91,939 shares — an estimated $2.52M sold.

PKO Investment Management Joint-Stock first reported a position in NTLA in Q2 2017 and held it in 5 quarters. The position peaked at $3.14M in Q1 2018. 157 funds tracked by Wall St. Rank hold NTLA as of Q3 2018.

PKO Investment Management Joint-Stock reported no remaining Intellia Therapeutics position as of Q3 2018 after selling out during the quarter.
PKO Investment Management Joint-Stock sold 91,939 Intellia Therapeutics shares in Q3 2018, an estimated $2.52M.
PKO Investment Management Joint-Stock first reported a position in Intellia Therapeutics in Q2 2017 and held it in 5 quarters.
PKO Investment Management Joint-Stock's Intellia Therapeutics position peaked at $3.14M in Q1 2018.
157 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2018.

Based on PKO Investment Management Joint-Stock's 13F filing for Q3 2018, filed 13 Mar 2025.